This result indicates that the potency of PPARδ activation in preventing LPS/D-GalN-induced acute liver failure might be much higher than it is currently thought to be, and it also suggests that GW501516 can be a powerful agent for managing ALF in clinical settings. The gene discussed is PPARD; the disease is acute liver failure.